InventisBio (SH:688382) Zhi Tong Cai Jing·2026-01-02 02:41Core Viewpoint - Yifang Biotechnology (Shanghai) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] Company Overview - Yifang Biotechnology is a research-driven biopharmaceutical company based in China, focusing on significant unmet medical needs in oncology, autoimmune diseases, and metabolic disorders [4] - As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products (BPI-D0316 and D-1553), two core clinical-stage products (D-2570 and D-0502), one clinical-stage candidate (D-0120), and three preclinical candidates (YF087, YF550, and YF057) [4] - The two key products, BPI-D0316 (a third-generation EGFR inhibitor) and D-1553 (a KRAS G12C inhibitor), have been approved for marketing in China and included in the National Reimbursement Drug List (NRDL) [4][5] Financial Information - For the fiscal year ending December 31, 2024, the company reported revenues of approximately RMB 168.79 million, with a gross profit of RMB 164.77 million [7][8] - The company recorded a net loss of approximately RMB 240.20 million for the fiscal year ending December 31, 2024 [9] - The revenue from the largest customer accounted for 90.3% of total revenue for the fiscal year ending December 31, 2024, and 73.6% for the nine months ending September 30, 2025 [6] Industry Overview - The global oncology drug market has grown from USD 143.5 billion in 2019 to an estimated USD 253.3 billion in 2024, with a compound annual growth rate (CAGR) of 12.0% [11] - The Chinese oncology drug market has increased from USD 26.5 billion in 2019 to USD 35.9 billion in 2024, with a CAGR of 6.3% [11] - The global targeted oncology drug market is projected to grow from USD 85.5 billion in 2019 to USD 154 billion in 2024, with a CAGR of 12.5% [14] - The Chinese targeted oncology drug market is expected to rise from USD 6.2 billion in 2019 to USD 16.6 billion in 2024, with a CAGR of 21.8% [14] Product Pipeline Insights - D-2570 is a TYK2 allosteric inhibitor in development for treating plaque psoriasis and ulcerative colitis (UC) [16] - The global market for psoriasis drugs is projected to reach USD 23.9 billion in 2024, with the Chinese market expected to grow to USD 2.5 billion [17] - The global UC drug market is anticipated to grow from USD 5.1 billion in 2019 to USD 9 billion in 2024 [18] - The global SERD drug market is expected to reach USD 10 billion in 2024, with the Chinese market projected to grow to USD 2 billion [19]